KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Deferred Taxes (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Deferred Taxes for 10 consecutive years, with $19.0 million as the latest value for Q4 2025.

  • Quarterly Deferred Taxes rose 26493.06% to $19.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.2 million through Dec 2025, up 125.85% year-over-year, with the annual reading at $5.2 million for FY2025, 125.85% up from the prior year.
  • Deferred Taxes for Q4 2025 was $19.0 million at Supernus Pharmaceuticals, up from -$2.6 million in the prior quarter.
  • The five-year high for Deferred Taxes was $19.0 million in Q4 2025, with the low at -$13.0 million in Q1 2022.
  • Average Deferred Taxes over 5 years is -$3.6 million, with a median of -$4.3 million recorded in 2021.
  • The sharpest move saw Deferred Taxes plummeted 1160.23% in 2024, then skyrocketed 26493.06% in 2025.
  • Over 5 years, Deferred Taxes stood at -$4.5 million in 2021, then plummeted by 71.87% to -$7.8 million in 2022, then plummeted by 34.78% to -$10.5 million in 2023, then soared by 99.31% to -$72000.0 in 2024, then surged by 26493.06% to $19.0 million in 2025.
  • According to Business Quant data, Deferred Taxes over the past three periods came in at $19.0 million, -$2.6 million, and -$7.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.